Skip to Main Content

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

Conditions

Diseases of the Digestive System - Liver

Phase II

What is the purpose of this trial?

This study evaluates HTD1801 in the treatment of Primary Sclerosing Cholangitis (PSC) in adults. The subjects will be randomised to 3 treatment groups, to receive 500mg, 1000mg and placebo, bid.

  • Trial with
    HighTide Biopharma Pty. Ltd.
  • Start Date
    06/28/2018
  • End Date
    11/29/2018
Trial Image

For more information about this study, contact:

Laura Cusack

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    07/03/2018
  • Study HIC
    #2000022820